|Year : 2018 | Volume
| Issue : 4 | Page : 458-464
Respiratory syncytial virus infections in India: Epidemiology and need for vaccine
Shobha Broor1, Shama Parveen2, Megha Maheshwari3
1 Department of Microbiology, Faculty of Medicine and Health Sciences, SGT University, Gurugram, Haryana, India
2 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India
3 Department of Microbiology, Dr. Baba Saheb Ambedkar Medical College and Hospital, New Delhi, India
|Date of Web Publication||18-Mar-2019|
Dr. Shobha Broor
Department of Microbiology, Faculty of Medicine and Health Sciences, SGT University, Gurugram - 122 005, Haryana
Source of Support: None, Conflict of Interest: None
Respiratory syncytial virus (RSV) has been identified as a leading cause of lower respiratory tract infections in young children and elderly. It is an enveloped negative-sense RNA virus belonging to Genus Orthopneumovirus. The clinical features of RSV infection range from mild upper-respiratory-tract illnesses or otitis media to severe lower-respiratory-tract illnesses. Current estimates show that about 33.1 million episodes of RSV-acute lower respiratory infection (ALRI) occurred in young children in 2015, of these majority that is, about 30 million RSV-ALRI episodes occurred in low-middle-income countries. In India, the rates of RSV detection in various hospital- and community-based studies mostly done in children vary from 5% to 54% and from 8% to 15%, respectively. Globally, RSV epidemics start in the South moving to the North. In India, RSV mainly peaks in winter in North India and some correlation with low temperature has been observed. Different genotypes of Group A (GA2, GA5, NA1 and ON1) and Group B (GB2, SAB4 and BA) have been described from India. The burden of RSV globally has kept it a high priority for vaccine development. After nearly 50 years of attempts, there is still no licensed vaccine and challenges to obtain a safe and effective vaccine is still facing the scientific community. The data in this review have been extracted from PubMed using the keywords RSV and Epidemiology and India. The data have been synthesised by the authors.
Keywords: Acute lower respiratory infection, acute respiratory infection, epidemiology, India, respiratory syncytial virus
|How to cite this article:|
Broor S, Parveen S, Maheshwari M. Respiratory syncytial virus infections in India: Epidemiology and need for vaccine. Indian J Med Microbiol 2018;36:458-64
|How to cite this URL:|
Broor S, Parveen S, Maheshwari M. Respiratory syncytial virus infections in India: Epidemiology and need for vaccine. Indian J Med Microbiol [serial online] 2018 [cited 2020 Apr 6];36:458-64. Available from: http://www.ijmm.org/text.asp?2018/36/4/458/254408
| ~ Introduction|| |
Respiratory syncytial virus (RSV) has been identified as one of the most important causative agents of lower respiratory tract infections (LRTIs) in young children and elderly worldwide.,, It is one of the most important infections of childhood and is associated with significant morbidity and mortality, especially in low- and middle-income countries (LMIC). Despite huge disease burden due to RSV so far, the development of RSV vaccine has lagged behind. However, in recent years, with the advances in understanding of RSV immunopathology and innovation in immunogen design, a number of RSV vaccines and monoclonal antibodies are in the pipeline. It is important to understand the epidemiology of an infectious disease before vaccine can be launched, and thus all over the world, there has been a surge in studies on RSV epidemiology, including India. This review presents a summary of information available on RSV epidemiology in India.
| ~ Respiratory Syncytial Virus|| |
RSV is an enveloped negative-sense RNA virus belonging to the order Mononegavirales, family Pneumoviridae and Genus Orthopneumovirus. The unsegmented RNA is about 15200 nucleotides long and codes for 11 structural and non-structural proteins. The envelope contains glycoproteins G, F and SH of which G protein is the cell-attachment protein and is most variable. F protein is the fusion protein and induces syncytia formation. Both G and F proteins induce neutralising and non-neutralising antibodies. According to the reactivity of RSV with monoclonal antibodies against G glycoprotein, the virus is divided into two major antigenic groups as follows: Group A and Group B. The RSV group A is further subdivided into 14 genotypes, GA1-GA7, SAA1, SAA2, NA1-NA4 and ON1, and the RSV group B has 27 genotypes: BA1-BA 12, BA-C, SAB1-SAB4, GB1-GB4, URU1, URU2, CB-B, CB1, BACCB and BACCA.
| ~ Viruses and Acute Respiratory Infection|| |
Acute respiratory infections (ARIs) account for 20%–40% of outpatient and 12%–35% of inpatient attendance in a hospital. Viruses account for 50%–90% of acute LRTI (ALRTI). Majority (80%) of identified viruses include RSV, influenza A and B, human parainfluenza viruses and Human metapneumovirus. Human RSV is the leading cause of LRTIs in infants and younger children worldwide.
| ~ Clinical Features of Respiratory Syncytial Virus Infection|| |
The clinical features of RSV infection range from mild upper-respiratory-tract illnesses or otitis media to severe lower-respiratory-tract illnesses. RSV is the most important cause of LRTI that is, bronchiolitis and pneumonia and sometimes croup, especially in young children <1-year old. Infection with this virus occurs during the 1st year of life in 50% of children and 20%–40% of them have signs of LRTI (bronchiolitis or pneumonia). Virus at first multiplies in the nasopharynx and then spreads to the lower respiratory tract, the incubation period is 3–5 days and reinfections are common in both children and adults. The presence of signs of wheeze, chest in-drawing, tachypnoea and crepitation had significantly higher odds of being present in RSV positive versus RSV negative. Underlying medical conditions, such as prematurity, congenital heart disease or chronic lung diseases, are associated with an increased risk of RSV hospitalisation and mortality., Prematurity, low birth weight, male siblings, maternal smoking, history of atopy, no breastfeeding and crowding (≥7 persons in household) have been reported to be significantly associated with RSV-associated acute lower respiratory infection (ALRI) as reported in a meta-analysis of risk factors for RSV.
RSV infections in adults are usually secondary infections and are mild to moderate in severity, unless underlying risk factors are present such as frail elderly living at home or in long-term care facilities, underlying chronic pulmonary disease or circulatory disease and the severely immunocompromised. Infections in immunocompromised and post-transplant individuals can be severe. The mortality rate of RSV in transplant recipients is significantly higher than in the general population. In a 2-year retrospective study, in RSV-positive patients, there was significant morbidity and mortality among haematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid-organ transplant patients (13.3%, 60-day mortality) and chronic obstructive pulmonary disease patients (12.8%, 60-day mortality).
| ~ Global Respiratory Syncytial Virus Epidemiology and Disease Burden|| |
Globally, ALRI is the leading causes of morbidity and mortality in under-five children. Human RSV is among the most common pathogen identified in children with ALRI. In a recent meta-analysis, it has been estimated that about 33.1 million episodes of RSV-ALRI occurred in young children in 2015, of these majority that is, about 30 million RSV-ALRI episodes occurred in LMIC, of which about a third occurred during the 1st year of life, whereas in high-income countries (HIC) only an estimated 2.8 million RSV-ALRI episodes occurred, thus the burden of RSV was more than ten times in LMIC and middle-income countries as compared to HIC. RSV-ALRI resulted in about 3.2 million (2.7–3.8) hospital admissions and 59,600 (48,000–74,500) in-hospital deaths in children younger than 5 years. The incidence of severe RSV-ALRI in infants is twice or three times greater than is reported for children <5 years overall. In children younger than 6 months, 1.4 million (UR 1.2–1.7) hospital admissions and 27,300 (UR 20,700–36,200) in-hospital deaths were due to RSV-ALRI of which a large number were in neonates who often present as apnoea or sepsis.
In 2015, RSV-associated ALRI incidence in developing countries was twice that of industrialised countries. However, these estimates are based on limited data from India.
| ~ Acute Respiratory Infection in India|| |
About 2.5 million children die each year in India, ~1/5 due to ALRI. ARI accounts for 17%–25% of all deaths in under-fives and ARI mortality is about 27/1000 in rural India. It has been estimated that about 20%–40% of all outpatient visits and 12%–35% of indoor admissions are due to ARIs. The rates of ARI were estimated to be 3.67 attacks/child/year in under-five from rural community near Delhi of which 14.7% were ALRTI.
| ~ Respiratory Syncytial Virus in India|| |
The rates of RSV detection in various hospital-based studies mostly done in children vary from 5% to 54% [Table 1].,,,,,,,,,,,,,,,,,,,,,,, These differences in rates of RSV detection are due to the selection of patients, their age group and the method used for RSV diagnosis. Most of the recent studies, which have used molecular techniques, show rates varying from 15% to 22%. However, studies employing antigen detection methods such as ELISA or immunochromatography have a very high rate of RSV detection, which may be due to the high false positivity of these methods. In a study conducted at AIIMS, New Delhi, it was observed that substantial number of LRTIs in children below 5 years of age is due to viral pathogens in India (44.5%). RSV was detected in 17% of children hospitalised with ALRI by centrifugation-enhanced culture. RSV was a major pathogen (26%) in children with bronchiolitis.
|Table 1: Respiratory syncytial virus in hospital-based studies in India (1971-2018)|
Click here to view
There have been a few community-based studies in India where also the rates of RSV detection vary from 8% to 15% depending on the methodology used and the study site [Table 2]. The incidence rates of RSV infection in these community studies from Ballabhgarh were 234 (192–281)/1000 child years in the study by Broor et al. and 420 (350–500)/1000 child years in the later study by Krishnan et al. In the previous study, immunofluorescence assay (IFA) was done for RSV detection but later study used real-time reverse transcription-polymerase chain reaction (PCR) for RSV detection which may account for the higher rates seen in the later study. The highest incidence rates were seen in infants in the study by Broor et al. that is, 324/1000 child years. Global estimates of incidence of RSV-associated severe ALRI are 75 (31–180)/10,000 child years. Average annual incidence of RSV-associated hospitalisation/1000 child years from Ballabhgarh among 0–23-month-old children was 7.4, as compared to 0.5 among 24–59 months old signifying that most of the burden of RSV-associated hospitalisation is among children under 2 years of age.
|Table 2: Respiratory syncytial virus in community-based studies in India|
Click here to view
| ~ Seasonality of Respiratory Syncytial Virus|| |
To optimise the prevention, diagnosis and treatment of RSV infection in a timely manner, knowledge about the differences in the timing of the RSV peak activity in different geographical regions is needed. Globally, RSV epidemics start in the South moving to the North. In a study on global seasonality of RSV, it was observed that RSV waves in Southern hemisphere start between March and June and in the Northern Hemisphere between September and December. Decrease in RSV activity was observed from August to October in the Southern Hemisphere and from February to May in the Northern Hemisphere. However, RSV lingers for a long period (up to 10 months) in countries with humid and rainy season near the equator. In temperate climates, RSV activity correlates with decrease in temperature, whereas in tropical countries, RSV activity is seen mainly in rainy season with some residual activity through the year. The information from middle- and low-income countries on RSV epidemiology and seasonality is scarce as most of these regions lack RSV surveillance networks. To this respect, the WHO through the Global Influenza Surveillance and Response System has implemented a pilot of RSV surveillance based on the influenza surveillance platform, with 14 countries selected covering for each of the WHO regions.
In India, RSV mainly peaks in winter in North India and some correlation with low temperature has been observed., In Odisha, respiratory virus infections showed seasonal variation, with peaks during the rainy season followed by winter season, whereas in Kolkata, RSV infection was predominant during November–February.
| ~ Molecular Epidemiology of Respiratory Syncytial Virus in India|| |
Limited studies from India have investigated molecular epidemiology of RSV. These included detection of RSV in clinical samples using modern diagnostic tools such as PCR and real-time PCR. The RSV strains were then characterised by DNA sequencing, followed by phylogenetic, Bayesian and Network analyses. The RSV strains were classified into genotypes by phylogenetic analysis. Both Groups A and B RSV have been reported from India [Table 3].,,,,, Different genotypes of Group A (GA2, GA5, NA1 and ON1) and Group B (GB2, SAB4 and BA) have been described from India. BA genotype of Group B has 60 bp duplication and ON1 genotype of Group A has 72 bp duplication in the G gene.
|Table 3: Molecular epidemiological studies of respiratory syncytial virus from India|
Click here to view
The origin or time to most recent common ancestor (tMRCA) and evolutionary rates were determined using Bayesian methods. Two recent studies from New Delhi carried out comprehensive evolutionary dynamics of Groups A and B RSV., This study reported tMRCA of Group A and NA1 genotype to be years 1953 and 2000, respectively. Similarly, Group B originated in years 1955, BA in 1995 and BA9 in 2000. The evolutionary rates of Group A and NA1 genotype were estimated to be 3.49 × 10−3 and 3.56 × 10−3, respectively, in this study. Similarly, the nucleotide substitution rates for Group A, BA genotype and BA9 lineage were estimated to be 4.59 × 10−3, 4.58 × 10−3 and 4.03 × 10−3, respectively. The relation among the haplotypes for NA1 genotype of Group A and BA9 lineage of BA genotype of Group B was determined using network analysis. Further, the molecular analysis of the RSV strains was done by mutational, glycosylation, selection pressure and entropy analyses. Two full genomes of Group A RSV were reported from Pune in 2013.
| ~ Respiratory Syncytial Virus Vaccines|| |
The burden of RSV globally has kept it a high priority for vaccine development. After nearly 50 years of attempts, there is still no licensed vaccine and challenges to obtain a safe and effective vaccine is still facing the scientific community.
The epidemiology and burden of RSV disease suggest that there are at least four distinct target populations for RSV vaccines:
- Infants (<6 months of age) who have the highest risk of severe disease
- Children >6 months of age to prevent disease in them and reduce potential transmission to younger children and the elderly
- Pregnant women to protect newborns both by transplacental transfer of antibodies and by blocking transmission
Recognition of the importance of RSV as an acute cause of paediatric morbidity and mortality has led to a surge in RSV vaccine and monoclonal antibody development, with more than 16 vaccine or monoclonal antibody candidates currently being assessed in clinical trials. The first candidate vaccine, formalin-inactivated RSV was associated with enhanced disease and two deaths upon subsequent natural RSV infection. This occurred in children under 2 years of age but not in older children, possibly because among the older children prior natural infection established a safer immune response pattern before vaccination. This experience delayed the development of RSV vaccine for many years and it has been difficult to achieve the right balance of safety and immunogenicity/efficacy for RSV vaccines. A number of RSV vaccine candidates are under development or in different phases of clinical trial. These include the following:
- Live-attenuated RSV vaccines which have been in development for decades. These live vaccines do not cause enhanced disease in RSV-naïve infants. Recent approaches include engineered viruses such as (a) 'knock-out' viruses that are attenuated but still immunogenic, such as the M2-2 deletion mutant that favours transcription over-replication of the genome leading to more protein production but limited virus production and (b) naturally attenuated chimeric viruses combining genes from RSV-related viruses such as Sendai, parainfluenza virus and bovine RSV
- Protein-based vaccines which include whole-inactivated virus, subunit antigens that associate to form aggregate particles and non-particle-based subunit antigens. These vaccines are mainly for protecting elderly populations from severe disease and are often formulated with an adjuvant. Particle and protein-subunit vaccines are also being developed for immunisation during pregnancy to boost pre-existing immunity to increase transplacental transfer of RSV-specific antibody to infants
- Replication-competent and deficient Alphavirus, adenovirus and modified vaccinia virus Ankara vectors encoding RSV surface antigens are being developed for use in infant and paediatric populations. These vaccines elicit robust humoral and cellular immunity
- Nucleic acid vaccines using either plasmid DNA or messenger RNA encoding RSV antigens are being targeted to protect both paediatric and elderly populations. Combination approaches with DNA and protein are also in development
- RSV monoclonal antibodies include a modified version of the D25 mAb, which is specific for the neutralising epitope in antigenic site Ø on the pre-F confirmation of RSV F protein is being developed for passive prophylaxis in paediatric populations. Genetic modifications that increase potency and half-life may provide protection for an entire RSV season with a single dose.
Overall, 16 RSV candidates are currently advancing through Phase 1 to Phase 3 clinical trials.
Most LMIC, where the RSV disease burden is greatest, have little or no national data and low awareness on RSV as a cause of disease. This gap in knowledge may hamper and delay evidence-based policy decisions with respect to any new RSV vaccine in LMIC. India is one of these countries where RSV infections impose a significant burden among under-five children and are among major causes of pneumonia mortality in India. RSV infections are also a problem among elderly, which is more neglected. The need for RSV vaccine for India is very obvious and crucial, but RSV epidemiology is not well documented in India. There are very few community-based studies describing the burden of RSV disease and hospitalisation. There is a need for teamwork of microbiologists, paediatricians and public health experts to understand the disease burden and seasonality of RSV infections in a vast country like India.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| ~ References|| |
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-59.
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al.
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010;375:1545-55.
Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets 2012;12:92-7.
Shi T, McAllister DA, O'Brien KL, Simoes EA, Madhi SA, Gessner BD, et al.
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. Lancet 2017;390:946-58.
Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development – A global Agenda. Vaccine 2016;34:2870-5.
Amarasinghe GK, BÁ o Y, Basler CF, Bavari S, Beer M, Bejerman N, et al.
Taxonomy of the order mononegavirales: Update 2017. Arch Virol 2017;162:2493-504.
Cane P, editor. Molecular epidemiology and evolution of RSV. In: Respiratory Syncytial Virus. Amsterdam: Elsevier; 2007. p. 89-113.
Mufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985;66 (Pt 10):2111-24.
Ren L, Xia Q, Xiao Q, Zhou L, Zang N, Long X, et al.
The genetic variability of glycoproteins among respiratory syncytial virus subtype A in China between 2009 and 2013. Infect Genet Evol 2014;27:339-47.
Zheng Y, Liu L, Wang S, Li Z, Hou M, Li J, et al.
Prevailing genotype distribution and characteristics of human respiratory syncytial virus in Northeastern China. J Med Virol 2017;89:222-33.
Jain N, Lodha R, Kabra SK. Upper respiratory tract infections. Indian J Pediatr 2001;68:1135-8.
Glezen WP, Loda FA, Clyde WA Jr. Senior RJ, Sheaffer CI, Conley WG, et al.
Epidemiologic patterns of acute lower respiratory disease of children in a pediatric group practice. J Pediatr 1971;78:397-406.
Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973;288:498-505.
Saha S, Pandey BG, Choudekar A, Krishnan A, Gerber SI, Rai SK, et al.
Evaluation of case definitions for estimation of respiratory syncytial virus associated hospitalizations among children in a rural community of Northern India. J Glob Health 2015;5:010419.
Liu W, Chen D, Tan W, Xu D, Qiu S, Zeng Z, et al.
Epidemiology and clinical presentations of respiratory syncytial virus subgroups A and B detected with multiplex real-time PCR. PLoS One 2016;11:e0165108.
Savić N, Janković B, Minić P, Vasiljević Z, Sovtić A, Pejić K, et al.
Clinical characteristics of respiratory syncytial virus infection in neonates and young infants. Vojnosanit Pregl 2011;68:220-4.
Bulkow LR, Singleton RJ, Karron RA, Harrison LH, Alaska RSV Study Group. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002;109:210-6.
Welliver RC Sr., Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB, et al.
Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010;26:2175-81.
Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ, et al.
Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. J Glob Health 2015;5:020416.
Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets 2012;12:98-102.
Anderson NW, Binnicker MJ, Harris DM, Chirila RM, Brumble L, Mandrekar J, et al.
Morbidity and mortality among patients with respiratory syncytial virus infection: A 2-year retrospective review. Diagn Microbiol Infect Dis 2016;85:367-71.
Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25-32.
Steinhoff MC, Padmini B, John TJ, Kingsley J, Pereira SM. Viral etiology of acute respiratory infections in South Indian children. Indian J Med Res 1985;81:349-53.
Reddaiah VP, Kapoor SK. Acute respiratory infections in rural underfives. Indian J Pediatr 1988;55:424-6.
Agarwal SC, Bardoloi JN, Mehta S. Respiratory syncytial virus infection in infancy and childhood in a community in Chandigarh. Indian J Med Res 1971;59:19-25.
Subramanian S, Prakash SK, Sukumar S, Lakshminarayana CS. Respiratory syncytial virus infections in Madras. Indian J Med Res 1980;72:317-26.
John TJ, Cherian T, Steinhoff MC, Simoes EA, John M. Etiology of acute respiratory infections in children in tropical Southern India. Rev Infect Dis 1991;13 Suppl 6:S463-9.
Jain A, Pande A, Misra PK, Mathur A, Chaturvedi UC. An Indian hospital study of viral causes of acute respiratory infection in children. J Med Microbiol 1991;35:219-23.
Chattopadhya D, Chatterjee R, Anand VK, Kumari S, Patwari AK. Lower respiratory tract infection in hospitalized children due to respiratory syncytial (RS) virus during a suspected epidemic period of RS virus in Delhi. J Trop Pediatr 1992;38:68-73.
Patwari AK, Bisht S, Srinivasan A, Deb M, Chattopadhya D. Aetiology of pneumonia in hospitalized children. J Trop Pediatr 1996;42:15-20.
Maitreyi RS, Broor S, Kabra SK, Ghosh M, Seth P, Dar L, et al.
Rapid detection of respiratory viruses by centrifugation enhanced cultures from children with acute lower respiratory tract infections. J Clin Virol 2000;16:41-7.
Yeolekar LR, Damle RG, Kamat AN, Khude MR, Simha V, Pandit AN, et al.
Respiratory viruses in acute respiratory tract infections in Western India. Indian J Pediatr 2008;75:341-5.
Bharaj P, Sullender WM, Kabra SK, Mani K, Cherian J, Tyagi V, et al.
Respiratory viral infections detected by multiplex PCR among pediatric patients with lower respiratory tract infections seen at an urban hospital in Delhi from 2005 to 2007. Virol J 2009;6:89.
Agrawal AS, Sarkar M, Chakrabarti S, Rajendran K, Kaur H, Mishra AC, et al.
Comparative evaluation of real-time PCR and conventional RT-PCR during a 2 year surveillance for influenza and respiratory syncytial virus among children with acute respiratory infections in Kolkata, India, reveals a distinct seasonality of infection. J Med Microbiol 2009;58:1616-22.
Hemalatha R, Swetha GK, Seshacharyulu M, Radhakrishna KV. Respiratory syncitial virus in children with acute respiratory infections. Indian J Pediatr 2010;77:755-8.
Gupta S, Shamsundar R, Shet A, Chawan R, Srinivasa H. Prevalence of respiratory syncytial virus infection among hospitalized children presenting with acute lower respiratory tract infections. Indian J Pediatr 2011;78:1495-7.
Choudhary ML, Anand SP, Heydari M, Rane G, Potdar VA, Chadha MS, et al.
Development of a multiplex one step RT-PCR that detects eighteen respiratory viruses in clinical specimens and comparison with real time RT-PCR. J Virol Methods 2013;189:15-9.
Biswas D, Yadav K, Borkakoty B, Mahanta J. Molecular characterization of human respiratory syncytial virus NA1 and GA5 genotypes detected in Assam in Northeast India, 2009-2012. J Med Virol 2013;85:1639-44.
Mazumdar J, Chawla-Sarkar M, Rajendran K, Ganguly A, Sarkar UK, Ghosh S, et al.
Burden of respiratory tract infections among paediatric in and out-patient units during 2010-11. Eur Rev Med Pharmacol Sci 2013;17:802-8.
Singh AK, Jain A, Jain B, Singh KP, Dangi T, Mohan M, et al.
Viral aetiology of acute lower respiratory tract illness in hospitalised paediatric patients of a tertiary hospital: One year prospective study. Indian J Med Microbiol 2014;32:13-8.
] [Full text]
Mathew JL, Singhi S, Ray P, Hagel E, Saghafian-Hedengren S, Bansal A, et al.
Etiology of community acquired pneumonia among children in India: Prospective, cohort study. J Glob Health 2015;5:050418.
Gaur B, Saha S, Iuliano, AD, Rai S, Krishnan A, Jain S, et al
. Use of Taqman Array Card for detection of respiratory viral pathogens in children under five years old hospitalized with acute medical illness in Ballabgarh, India” submitted for publication to Indian journal of Medical Microbiology.
Mishra P, Nayak L, Das RR, Dwibedi B, Singh A. Viral agents causing acute respiratory infections in children under five: A study from Eastern India. Indian J Med Microbiol 2017;35:134-6.
Panda S, Mohakud NK, Suar M, Kumar S. Etiology, seasonality, and clinical characteristics of respiratory viruses in children with respiratory tract infections in eastern India (Bhubaneswar, Odisha). J Med Virol 2017;89:553-8.
Sahu M, Kori BK, Sahare L, Barde PV. Respiratory syncytial virus in children with influenza-like illness. Indian Pediatr 2015;52:339-40.
Saxena S, Singh D, Zia A, Umrao J, Srivastava N, Pandey A, et al.
Clinical characterization of influenza A and human respiratory syncytial virus among patients with influenza like illness. J Med Virol 2017;89:49-54.
Swamy MA, Malhotra B, Reddy PV, Tiwari JK, Kumar N, Gupta ML, et al.
Trends of respiratory syncytial virus sub-types in children hospitalised at a tertiary care centre in Jaipur during 2012-2014. Indian J Med Microbiol 2017;35:134-6.
] [Full text]
Broor S, Parveen S, Bharaj P, Prasad VS, Srinivasulu KN, Sumanth KM, et al.
A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PLoS One 2007;2:e491.
Krishnan A, Kumar R, Broor S, Gopal G, Saha S, Choudekar A, et al
. Epidemiology of viral acute lower respiratory infections in a community-based cohort of rural North Indian children.
Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O, et al.
Respiratory syncytial virus seasonality: A global overview. J Infect Dis 2018;217:1356-64.
Parveen S, Sullender WM, Fowler K, Lefkowitz EJ, Kapoor SK, Broor S, et al.
Genetic variability in the G protein gene of group A and B respiratory syncytial viruses from India. J Clin Microbiol 2006;44:3055-64.
Patil SL, Balakrishnan A. Genetic characterization respiratory syncytial virus in Kerala, the Southern part of India. J Med Virol 2017;89:2092-7.
Agrawal AS, Sarkar M, Ghosh S, Chawla-Sarkar M, Chakraborty N, Basak M, et al.
Prevalence of respiratory syncytial virus group B genotype BA-IV strains among children with acute respiratory tract infection in Kolkata, Eastern India. J Clin Virol 2009;45:358-61.
Raghuram SV, Khan WH, Deeba F, Sullender W, Broor S, Parveen S, et al.
Retrospective phylogenetic analysis of circulating BA genotype of human respiratory syncytial virus with 60 bp duplication from New Delhi, India during 2007-2010. Virusdisease 2015;26:276-81.
Haider MS, Khan WH, Deeba F, Ali S, Ahmed A, Naqvi IH, et al.
BA9 lineage of respiratory syncytial virus from across the globe and its evolutionary dynamics. PLoS One 2018;13:e0193525.
Haider MS, Deeba F, Khan WH, Naqvi IH, Ali S, Ahmed A, et al.
Global distribution of NA1 genotype of respiratory syncytial virus and its evolutionary dynamics assessed from the past 11 years. Infect Genet Evol 2018;60:140-50.
Choudhary ML, Wadhwa BS, Jadhav SM, Chadha MS. Complete genome sequences of two human respiratory syncytial virus genotype A strains from India, RSV-A/NIV1114046/11 and RSV-A/NIV1114073/11. Genome Announc 2013;1. pii: e00165-13.
Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al.
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34.
[Table 1], [Table 2], [Table 3]